Endexo™ surface modifying macromolecules enhance the biocompatibility of medical devices that come in contact with blood or tissue. They are low molecular weight fluoro-oligomeric additives that bloom to the top few nanometers of the device surface, during the manufacturing process.
Therefore, the surface properties are that of a fluorinated surface, capable of inhibiting platelet activation and suppressing protein procoagulant conformation. Altogether, the effect is reduced thrombosis which both increases device functionality as well as reducing thrombus related complications such as DVTs (deep vein thrombosis) in catheter based applications.
Endexo™ platform technology has broad applicability. With 70+ formulations, the Endexo technology can be used with a variety of base polymers (including polyurethane, polysulfone, PVC, polypropylene, silicone) and manufacturing techniques (such as melt extrusion, solution spinning, injection molding). The Endexo™ molecules become an integral part of the base material and provides extended efficacy of treatment compared to traditional coatings.
Average reduction across 8500 BioFlo PICCs studied:
As reported by AngioDynamics
Blood Contacting Devices
Dialyzers (licensed exclusively to Fresenius Medical Care)
Dialysis blood lines (licensed exclusively to Fresenius Medical Care)
Non-dialysis blood lines
Medical Device Anti-fouling
Reduced protein adhesion
Reduced bacterial adhesion